IL128723A0 - Pharmaceutical compositions containing rar antagonists and rxr agonists - Google Patents
Pharmaceutical compositions containing rar antagonists and rxr agonistsInfo
- Publication number
- IL128723A0 IL128723A0 IL12872397A IL12872397A IL128723A0 IL 128723 A0 IL128723 A0 IL 128723A0 IL 12872397 A IL12872397 A IL 12872397A IL 12872397 A IL12872397 A IL 12872397A IL 128723 A0 IL128723 A0 IL 128723A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- antagonist
- rar
- rxr agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2477296P | 1996-08-28 | 1996-08-28 | |
PCT/US1997/015155 WO1998008546A2 (fr) | 1996-08-28 | 1997-08-28 | Combinaisons therapeutiques d'antagonistes de rar et d'agonistes de rxr |
Publications (1)
Publication Number | Publication Date |
---|---|
IL128723A0 true IL128723A0 (en) | 2000-01-31 |
Family
ID=21822317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12872397A IL128723A0 (en) | 1996-08-28 | 1997-08-28 | Pharmaceutical compositions containing rar antagonists and rxr agonists |
Country Status (11)
Country | Link |
---|---|
US (2) | US6130230A (fr) |
EP (1) | EP0928200B1 (fr) |
JP (1) | JP2001500486A (fr) |
AT (1) | ATE236654T1 (fr) |
AU (1) | AU731060B2 (fr) |
CA (1) | CA2263817A1 (fr) |
DE (1) | DE69720745T2 (fr) |
ES (1) | ES2196361T3 (fr) |
IL (1) | IL128723A0 (fr) |
NO (1) | NO990912L (fr) |
WO (1) | WO1998008546A2 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2344653A1 (fr) | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs |
CA2254429A1 (fr) * | 1998-11-19 | 2000-05-19 | Tully Michael Underhill | Compositions favorisant la chondrogenese |
WO2000061233A2 (fr) * | 1999-04-14 | 2000-10-19 | Allergan Sales, Inc. | Methodes et compositions de traitement et de prevention de maladies pulmonaires |
US6436993B1 (en) * | 1999-07-13 | 2002-08-20 | The Salk Institute For Biological Studies | Use of RAR antagonists as modulators of hormone mediated processes |
CA2402413A1 (fr) * | 2000-03-14 | 2001-09-20 | The University Of Western Ontario | Compositions et procedes exercant un effet sur l'osteogenese |
AU4866201A (en) * | 2000-04-13 | 2001-10-30 | Pierre Chambon | Compositions and methods for use in modulating immune system function |
EP1348033A2 (fr) | 2000-05-26 | 2003-10-01 | Board of Trustees of the University of Illinois | Reactifs et methodes destines a l'identification et a la modulation de l'expression de genes regules par les retinoides |
WO2002022113A2 (fr) | 2000-09-13 | 2002-03-21 | Bristol-Myers Squibb Company | Antagonistes vis-a-vis du recepteur d'acide retinoique, tenant lieu de promoteurs de l'angiogenese |
WO2002100827A2 (fr) * | 2001-06-11 | 2002-12-19 | Ludwig Institute For Cancer Research | Procede pour augmenter la survie de cellules secretant de la dopamine |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (fr) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methodes de developpement de cellules souches et de cellules precurseurs, populations de cellules multipliees obtenues a l'aide de ces methodes |
US20040097587A1 (en) * | 2002-03-27 | 2004-05-20 | Arbiser Jack L | Compositions and methods of treatment of ulcerating diseases, burns, and related conditions |
JP4473491B2 (ja) * | 2002-05-28 | 2010-06-02 | 株式会社資生堂 | 毛穴縮小剤 |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US20050112123A1 (en) * | 2003-10-06 | 2005-05-26 | Vaughan Michael R. | Methods of treating proteinuria |
GB2411115A (en) * | 2004-02-19 | 2005-08-24 | Medical Res Council | Retinoic acid antagonists for the treatment of oesophageal disorders |
WO2006030442A2 (fr) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methodes de culture ex vivo de cellules souches et de precurseur par co-culture avec des cellules mesenchymales |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP2181710A1 (fr) * | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Ligands pour la modulation de l'activité du récepteur gamma orphelin (NR1F3) |
EP2329817A1 (fr) * | 2009-09-04 | 2011-06-08 | Ernst-Moritz-Arndt-Universität Greifswald | Antagonistes du récepteur de l'acide rétinoïque, inhibiteurs de miR-10a et inhibiteurs des répresseurs HOXB1 et/ou HOXB3 pour le traitement du cancer du pancréas |
BR112013033309B1 (pt) | 2011-06-24 | 2022-07-05 | Gri Bio, Inc | Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i |
US20150064273A1 (en) | 2012-02-13 | 2015-03-05 | Gamida-Cell Ltd. | Mesenchymal Stem Cells Conditioned Medium and Methods of Generating and Using the Same |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9963439B2 (en) | 2013-08-20 | 2018-05-08 | University Of Washington Through Its Center For Commercialization | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase |
PL3380086T3 (pl) | 2015-11-25 | 2022-02-21 | Io Therapeutics, Inc. | Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu |
EP3468600A4 (fr) | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | Composés rétinoïdes et rexinoïdes sélectifs du récepteur et modulateurs immunitaires pour l'immunothérapie du cancer |
KR20200029544A (ko) | 2017-07-13 | 2020-03-18 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물 |
SG11202001479RA (en) | 2017-08-31 | 2020-03-30 | Io Therapeutics Inc | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
US12115140B2 (en) * | 2020-07-31 | 2024-10-15 | The Trustees Of Columbia University In The City Of New York | Method of treating adenoid cystic carcinoma |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992016658A1 (fr) | 1991-03-18 | 1992-10-01 | The Salk Institute For Biological Studies | Compositions a elements de reaction et dosages les incorporant |
US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
US5399586A (en) * | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
EP0659045A4 (fr) * | 1993-05-18 | 1997-02-26 | Inst Nat Sante Rech Med | Souris produite par genie genetique et comportant des modifications dans les genes codant les proteines du recepteur de l'acide retinoique. |
US5702914A (en) * | 1994-12-21 | 1997-12-30 | The Salk Institute For Biological Studies | Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements |
CA2210248A1 (fr) | 1995-01-13 | 1996-07-18 | Ronald M. Evans | Regulation allosterique de recepteurs d'hormones nucleaires |
US5747661A (en) * | 1995-01-13 | 1998-05-05 | Howard Hughes Medical Institute | Retinoid-inducible response elements |
US5559248A (en) * | 1995-04-05 | 1996-09-24 | Bristol-Myers Squibb Co. | Retinoid-like heterocycles |
US6025388A (en) * | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
US5906920A (en) | 1995-08-29 | 1999-05-25 | The Salk Institute For Biological Studies | Methods for the detection of ligands for retinoid X receptors |
AU5727998A (en) | 1996-12-31 | 1998-07-31 | Salk Institute For Biological Studies, The | Treatment of liposarcomas using a combination of thiazolidinediones and retinoidx receptor selective agonists |
CA2276288A1 (fr) | 1996-12-31 | 1998-07-09 | Laszlo Nagy | Traitement des etats pathologiques generes par la proliferation cellulaire neoplasique au moyen d'activateurs ppar-gamma et compositions utiles a cet effet |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
-
1997
- 1997-08-28 DE DE69720745T patent/DE69720745T2/de not_active Expired - Fee Related
- 1997-08-28 WO PCT/US1997/015155 patent/WO1998008546A2/fr active IP Right Grant
- 1997-08-28 ES ES97939631T patent/ES2196361T3/es not_active Expired - Lifetime
- 1997-08-28 EP EP97939631A patent/EP0928200B1/fr not_active Expired - Lifetime
- 1997-08-28 AU AU41674/97A patent/AU731060B2/en not_active Ceased
- 1997-08-28 CA CA002263817A patent/CA2263817A1/fr not_active Abandoned
- 1997-08-28 AT AT97939631T patent/ATE236654T1/de not_active IP Right Cessation
- 1997-08-28 IL IL12872397A patent/IL128723A0/xx unknown
- 1997-08-28 JP JP10511906A patent/JP2001500486A/ja not_active Ceased
- 1997-08-28 US US08/919,318 patent/US6130230A/en not_active Expired - Lifetime
-
1999
- 1999-02-25 NO NO990912A patent/NO990912L/no not_active Application Discontinuation
-
2000
- 2000-07-19 US US09/619,308 patent/US6653322B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1998008546A8 (fr) | 2001-04-19 |
WO1998008546A3 (fr) | 1998-04-23 |
ATE236654T1 (de) | 2003-04-15 |
ES2196361T3 (es) | 2003-12-16 |
AU731060B2 (en) | 2001-03-22 |
AU4167497A (en) | 1998-03-19 |
NO990912L (no) | 1999-04-27 |
DE69720745D1 (de) | 2003-05-15 |
JP2001500486A (ja) | 2001-01-16 |
US6130230A (en) | 2000-10-10 |
DE69720745T2 (de) | 2004-02-26 |
US6653322B1 (en) | 2003-11-25 |
CA2263817A1 (fr) | 1998-03-05 |
EP0928200A2 (fr) | 1999-07-14 |
NO990912D0 (no) | 1999-02-25 |
WO1998008546A2 (fr) | 1998-03-05 |
EP0928200B1 (fr) | 2003-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL128723A0 (en) | Pharmaceutical compositions containing rar antagonists and rxr agonists | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
ATE258067T1 (de) | Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält | |
DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
DE69832712D1 (de) | Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen | |
MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
YU2603A (sh) | Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija | |
BR0008847A (pt) | Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
EA200200132A1 (ru) | СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ | |
MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
CA2156481A1 (fr) | Compositions antagonistes du recepteur 5-ht2, utiles pour le traitement des troubles veineux | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
EP1011672A4 (fr) | Composes et compositions pharmaceutiques les contenant a effet analgesique | |
MX9704887A (es) | Composiciones farmaceuticas para el tratamiento de trastornos depresivos. | |
WO2001090361A3 (fr) | Modulation des effets de protease sur des substrats de chimiokines |